New EU project to focus on membrane proteins with the aim of finding new treatments

A new, EU-funded project will investigate membrane proteins with the aim of finding new treatments for a range of diseases. Membrane proteins are responsible for transporting chemicals and messages between the inside and outside of cells, and they are vital for every process in the human body. Defective membrane proteins have been implicated in a range of human diseases, including diabetes, heart disease, epilepsy, depression, osteoporosis, stomach ulcers and cataracts.

Furthermore, the bacteria, yeasts and parasites which cause many infectious diseases also rely on their own membrane proteins, which could therefore be used as targets for the development of new drugs.

The €15 million EDICT ('European drug initiative for channels and transporters') project will focus its efforts on around 80 of these membrane proteins. The project partners will map out the structure of proteins involved in diseases to identify compounds that could be developed as treatments. Meanwhile for proteins whose structure is already known, the team hopes to make real advances towards new treatments.

"Membrane proteins are seen by many as the next potential source of drug development, and so the EC is keen to fund research in this area," said the project's coordinator, Professor Peter Henderson of the University of Leeds in the UK. "However, they are difficult to study and are poorly understood, though the recent sequencing of the human and other genomes show they make up about one third of all proteins in all organisms, including humans."

The four-year project brings together scientists from 27 organisations in 12 countries. Among the biologists, chemists and imaging experts involved in the project are two Nobel laureates. Professor Hartmut Michel of the Max Planck Institute for Biophysics in Germany received his award in 1988 for determining the three dimensional structure of a photosynthetic reaction centre, while 1997 laureate Professor Sir John Walker of the UK's Medical Research Council won his award for working out the enzymatic mechanism underlying the synthesis of adenosine triphosphate (ATP), which our cells use to store and transfer energy.

The drugs industry is also represented in the project, by the pharmaceutical giant AstraZeneca and a smaller company called Xention, which specialises in the discovery and development of ion channel drugs.

"At the moment, few groups of membrane proteins are being seriously investigated by the pharmaceutical industry, so this project will help to fill that gap," commented Professor Henderson. "By bringing together the best scientists in this challenging field from all over Europe, we hope to make a real advance towards new treatments for key diseases."

For further information, please visit:
http://www.leeds.ac.uk

Copyright ©European Communities, 2008
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

Salvat Laboratories announces submission of New Dr…

Salvat Laboratories announced that it has submitted a New Drug Application (NDA) to the FDA for the approval of the first ocular corticosteroid formulated in a nanoemulsi...

Pfizer's elranatamab granted FDA Breakthrough Ther…

Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administrati...

New insights on antibody responses to Omicron vari…

Knowing how well vaccination against one SARS-CoV-2 strain (with or without previous infection) counteracts infection with a different strain is a critical research quest...

Ancient viral DNA in human genome guards against i…

Viral DNA in human genomes, embedded there from ancient infections, serve as antivirals that protect human cells against certain present-day viruses, according to new res...

The origin-of-life molecule, a key to cancer resea…

RNA, the molecule that gave rise to life, has been shown to be essential for repairing human genetic material and preventing mutations that might lead to developing cance...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...